Serum Asprosin, Metabolic Syndrome, and Cardiometabolic Risk in Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a significantly increased risk of cardiovascular disease and metabolic syndrome (MetS). Asprosin is a recently identified adipokine involved in glucose regulation, insulin resistance, and systemic inflammation, but its role in the cardiometabolic complications of RA remains incompletely understood.

The purpose of this case-control study is to evaluate and compare serum Asprosin levels among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy control individuals. The study will also assess the association between serum Asprosin concentrations, RA disease activity (DAS28-ESR), and various cardiometabolic risk indices (including TyG index, Atherogenic Index of Plasma, and Castelli risk indices).

Participants will undergo a comprehensive clinical assessment, disease activity scoring, physical function evaluation using the Health Assessment Questionnaire (HAQ), and laboratory investigations including fasting blood tests and serum Asprosin measurement via ELISA. Findings from this study may help clarify the pathophysiological role of Asprosin in RA and improve cardiometabolic risk stratification in affected patients.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Rheumatoid Arthritis Arachnodactyly Arthritis Arthritis, Rheumatoid Autoimmune Diseases Cardiovascular Diseases Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Connective Tissue Diseases Glucose Metabolism Disorders Hyperinsulinism Immune System Diseases Insulin Resistance Joint Diseases Limb Deformities, Congenital Metabolic Diseases Metabolic Syndrome Musculoskeletal Abnormalities Musculoskeletal Diseases Nutritional and Metabolic Diseases Rheumatic Diseases Skin and Connective Tissue Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients aged 18 years or older.
Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria.
Ability and willingness to provide written informed consent.
Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases.

Exclusion criteria

Presence of other autoimmune diseases or overlap syndromes.
Active acute or chronic infectious diseases.
Pregnancy or lactation.
Current malignancy or previous history of malignancy.
Severe hepatic or renal impairment.
Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.

Treatment and study plan

Primary outcomes

Serum Asprosin Level

Time frame: Baseline

Serum asprosin concentration (measured in ng/mL) assessed via a commercial enzyme-linked immunosorbent assay (ELISA) kit to compare rheumatoid arthritis patients with metabolic syndrome versus rheumatoid arthritis patients without metabolic syndrome.

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Association of Serum Asprosin With Metabolic Syndrome and Cardiometabolic Risk in Patients With Rheumatoid Arthritis

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2027
First posted: Aug 31, 2026
Registry last updated: Aug 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed